-
Mashup Score: 11Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF - 3 year(s) ago
AbstractAims. The aim of this study was to examine the effect of dapagliflozin on the incidence of ventricular arrhythmias and sudden death in patients with hea
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 5interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management - 3 year(s) ago
Abstract. Type 2 diabetes mellitus (T2DM) portends high risk of atherosclerotic cardiovascular (CV) events and of CV mortality; moreover, this group of patients
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
👆#DAPA_HF : effect of #dapa on #VT/#VF/#SCD/#CAshe A further proof of the #SGLT2i Multiple mechanisms of benefit 👇(summary in 2020) Soon a new manuscript on the topic with @SABOURETCardio @DLBHATTMD #Germanova Thanking @DrMarthaGulati @MaasAngela https://t.co/lWcXsqy0kI https://t.co/BJPwwIfI6Z
-
-
Mashup Score: 15
Response to the positive findings was tempered, however, by the post hoc nature of the analysis, choice of primary outcome, and inconsistencies among key subgroups.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
Dapagliflozin might reduce the risk for ventricular arrhythmias and sudden death in patients with HFrEF, a post hoc analysis of the #DAPA-HF trial suggests. #ESC21 #ESCCongress https://t.co/Y5wb8qcWhg
-
-
Mashup Score: 1interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management - 4 year(s) ago
Abstract. Type 2 diabetes mellitus (T2DM) portends high risk of atherosclerotic cardiovascular (CV) events and of CV mortality; moreover, this group of patient
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Here #DAPA-CKD Commentary Completing the overview on #SGLT2i benefit ✅ #Prevention in #T2DM ✅#HFrEF irrespective of #DM ✅#CKD irrespective of #DM Here the citation to our recent review ❇️ https://t.co/SbcMnQsex9 @SABOURETCardio @radcliffeCARDIO @TomLuscher @ShelleyZieroth https://t.co/ZnFNVhrw8T https://t.co/9QfcIC45VP
-
-
Mashup Score: 23ESC | ESC CONGRESS 2020 | Live Sessions - 4 year(s) ago
Become a Member During “ESC Congress 2020 – The Digital Experience” your online activity is tracked and collected by the ESC. This will be used to allow us to provide CME credits should you request them; for reporting and statistical purposes; to assist in providing you with the best experience; to inform you about ESC…
Source: ESC2020 - The Digital ExperienceCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#DAPA-CKD trial: randomly allocated 4,304 #CKD patients with and without type 2 #diabetes to dapagliflozin 10 mg or placebo once daily for a median of 2.4 years https://t.co/06PiaEudZM #ESCCongress https://t.co/XMHNHhPQzH
-
#DAPA-CKD trial: in patients with #CKD dapagliflozin reduced the risk of #kidney failure, reduced the risk of #cardiovascular death or #heartfailure hospitalisation, and prolonged survival https://t.co/06PiaEudZM #ESCCongress https://t.co/xh97oW2YZZ
-
-
Mashup Score: 5
This exploratory analysis of a randomized trial examined the effect of dapagliflozin on a composite of worsening heart failure or cardiovascular death on individuals with heart failure with reduced ejection fraction with and without diabetes.
Source: jamanetwork.comCategories: CardiologistsTweet-
#DAPA-HF: Effect of Dapa on Worsening HF & CV-Death in #HF pts with/without Diabetes Dapa significantly improvedHF outcomes irrespective od Diabetic status @SABOURETCardio @MicheleSenni @iamritu @AnastasiaSMihai @hvanspall @ShelleyZieroth @mirvatalasnag https://t.co/yBxKTfAeAu https://t.co/5Y5T7ySyMc
-
-
Mashup Score: 1Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age | Circulation - 4 year(s) ago
Background: The DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) showed that dapagliflozin added to other guideline-recommended therapies reduced the risk of mortal…
Source: www.ahajournals.orgCategories: Cardiology News and JournalsTweet-
In #DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced risk of death & worsening HF across broad spectrum of ages, including the elderly. Read more: https://t.co/vDLI9AHNLE #AHAJournals @UofGICAMS https://t.co/e7ZNHnlLVm
-
-
Mashup Score: 0Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction | Circulation - 4 year(s) ago
Background: Goals of management in patients with heart failure and reduced ejection fraction include reducing death and hospitalizations, and improving health status (symptoms, physical function, a…
Source: www.ahajournals.orgCategories: Cardiology News and JournalsTweet-
In #DAPA-HF, the SGLT2 inhibitor dapagliflozin improved symptoms, physical function, and quality of life in patients with #HFrEF. Read more: https://t.co/Lm2kjx2tNr #AHAJournals @MkosiborodMD @MidAmericaHeart @UofGICAMS https://t.co/hcJL1Je5fp
-
#DAPA_HF subanalysis: #Dapa ⬇️ serious ventricular arrhythmia/ cardiac arrest / sudden death irrespective of presence of ICD/CRT at baseline Despite it’s a post-hoc analysis a further insight that is something more than just a “diuretic” @markcpetrie20 https://t.co/u5O4Zlilxc https://t.co/24ONMRtgvY